Cubist (NASDAQ:CBST) third quarter results turned out to be quite impressive. The main reason was growth in consumer demand and higher volume of hospital patients, which caused an increase in the company’s product line-up.

Cubist (NASDAQ:CBST) Recorded sales of $309.2 million on a year-over-year basis, which is an improvement by 16%. Sales estimates by analysts were $306.8 million. As a result of this increase company’s non-GAAP Earnings per Share for its third quarter went up to $0.58 as compared to $0.41 last year. EPS predicted by analysts was $0.40.

International sales for Cubist (NASDAQ:CBST) went up from last year’s figures of $13 million to $16.6 million in this year’s third quarter. Overall international sales for the first 3 quarters were recorded at $51.1 million as compared to last year’s $40.3 million.

Cash inflow for Cubist (NASDAQ:CBST) in its third quarter was recorded at $687 million, which was $578 million last year.

Cubist (NASDAQ:CBST)’S best selling drug proved to be Cubicin that is a treatment for skin infections of different types. Cubicin’s sales last year were $229.9 million, which went up to $256.7 million in this year’s third quarter. The drug got its first ever annual sales rate of a billion dollar.

Clostridium Difficile treatment by Cubist (NASDAQ:CBST) Called Dificid also had strong sales in company’s third quarter. For the first three quarters of 2014 total Dificid sales were $47.7 million. Cubist (NASDAQ:CBST) has every reason to consider Dificid a strong revenue generator in the future because around 700,000 clostridium difficile cases are reported in the US on an annual basis.

Another drug by Cubist (NASDAQ:CBST) called Entereg had a strong third quarter as well. The sales for Entereg went up resulting in third quarter revenue of $15.3 million; whereas its revenue last year was $13.7 million. For this year’s first 9 months Entereg had total sales of $43.8 million, which is quite an impressive figure by all standards. Back in 2011 GlaxoSmithKline (NYSE:GSK) gave away Entereg rights to Adolor, which was later acquired by Cubist (NASDAQ:CBST).

Staphylococcus Aureus treatment called Sivextro was launched by Cubist (NASDAQ:CBST) back in August; this treatment was engineered for adults. It was yet another hit by the company because its third quarter sales were recorded at $2.4 million within only weeks of its launch.

Future for Cubist (NASDAQ:CBST) looks extremely bright – a great news for its investors. Considering the fact that Sivextro only had a few weeks in Cubist (NASDAQ:CBST)’s third quarter it can be safely estimated that its sales in the fourth quarter will be even better; it will be one of the many drugs by the company that will act as strong revenue generators.

Cubist (NASDAQ:CBST) is waiting for its FDA approval for its latest UTI treatment drug called Zerbaxa, which could prove to be a great source of revenue for the company. Cubist (NASDAQ:CBST) is also looking for EU’s approval for the drug as well, which may come sometime next year.

Cubist (NASDAQ:CBST)’s growth in sales depend largely on the rising volume of hospitalized patients because most of its treatments are engineered to fight infections that are difficult to treat.